Biotech Bad News Buys

It's pretty common to see a biotech tank on any given day, so when three companies dropped substantially the other day, it wasn't that surprising. Unless you're an investor in the companies, of course.

Seattle Genetics (NASDAQ: SGEN  ) , which sells cancer drug Adcetris, dropped because revenue was only up 19%. While that wasn't exactly the growth investors were hoping for, Seattle Genetics still has a substantial pipeline worth owning.

Pharmacyclics (NASDAQ: PCYC  ) was another earnings "loser." During the first full quarter on the market, demand for its cancer drug, Imbruvica, came in at a little over $50 million. Despite getting a second approval in mid February for CLL, which is a larger market than mantle cell lymphoma that it was first approved for, Pharmacyclics guided for sales of just $295 million for the year.

Finally, Endocyte (NASDAQ: ECYT  ) was the loser of the group after announcing that its trial testing vintafolide in ovarian-cancer patients was stopped early for futility. Based on data to date, the data monitoring committee believes the trial won't be able to show that vintafolide increases in progression-free survival if Endocyte let it go to completion.

In the video below, senior biotech specialist Brian Orelli and health care analyst David Williamson discuss the drops and which companies might be bad-news buys.

"I'd rather buy a good company at a fair price than buy a fair company at a good price."
And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2959519, ~/Articles/ArticleHandler.aspx, 9/1/2015 10:26:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
ECYT $5.14 Down -0.13 -2.47%
Endocyte, Inc. CAPS Rating: ****
PCYC $0.00 Down +0.00 +0.00%
SGEN $39.32 Down -0.95 -2.36%
Seattle Genetics CAPS Rating: ***